Tyler Van Buren, an analyst from TD Cowen, has initiated a new Buy rating on NewAmsterdam Pharma Company (NAMS).
Tyler Van Buren’s rating is based on the exceptional potential of NewAmsterdam Pharma Company’s leading drug candidate, Obicetrapib. This oral CETP inhibitor has shown remarkable efficacy in its Phase I/II trials, achieving a median LDL-C reduction of about 47%, along with consistent improvements in other cardiac biomarkers. Obicetrapib stands out not only for its potency but also for its convenience as a once-daily oral therapy, which is appealing for a broad patient base. Furthermore, its potential to reduce diabetes risk by 25% positions it favorably as an add-on therapy to statins, which conversely increase diabetes risk. The drug’s monotherapy profile is strong, and its combination with ezetimibe in the Phase II ROSE2 trial resulted in even more impressive LDL-C reductions.
Van Buren’s Buy rating also reflects his confidence in the upcoming Phase III trial results, which are expected to further substantiate Obicetrapib’s profile. The trials, namely BROOKLYN, BROADWAY, and TANDEM, are set to report data over the next 12 months, with each addressing different patient populations and combination therapies. Van Buren’s anticipation of these results, which could set a new standard in LDL-C lowering and cardiac risk management, is bolstered by the strong management team at NewAmsterdam. His projections estimate that Obicetrapib could generate over $3 billion in global sales post its anticipated 2027 launch, which underscores the Buy rating’s foundation on both clinical and commercial potential.
In another report released on May 13, Piper Sandler also maintained a Buy rating on the stock with a $37.00 price target.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
NewAmsterdam Pharma Company (NAMS) Company Description:
Frazier Lifesciences Acquisition Corp is a blank check company.
Read More on NAMS:
